Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FCC Seeks Comment On Creating Its Own National “Do Not Call” Registry

This article was originally published in The Tan Sheet

Executive Summary

The Federal Communications Commission is requesting public input on its possible establishment of a national "do not call" list for telemarketers and how such action might be taken in conjunction with other federal or local registries

You may also be interested in...



FTC “Do Not Call” Registry Must Not Preempt State Efforts – AGs

State-run programs protecting consumers from unwanted telemarketing calls should not be preempted by the Federal Trade Commission's proposed changes to its "Do Not Call" registry, 49 state attorneys general underscore in April 12 comments to the agency

FTC “Do Not Call” Proposal Aims To Increase Telemarketing Restrictions

The Federal Trade Commission would expand its national "Do Not Call" registry, placing greater limitations on telemarketers, under proposed amendments to the agency's Telemarketing Sales Rule (TSR)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel